Tristel Regulatory News (TSTL)

TRISTEL plc

("Tristel" or the "Company")

Know-How License and Product Supply Agreement with

Byotrol plc ("Byotrol")

Tristel plc (AIM: TSTL), the manufacturer of infection prevention and contamination control products announces that it has entered into a know-how licence and commercial collaboration with Byotrol ("Agreement"). The Agreement relates to the joint development of a biocidal formulation and Byotrol's development of two additional biocidal products and formulations that will be supplied and licensed to Tristel. 

Jointly developed formulation

This formulation will create a unique surface disinfectant product for hospitals by combining the two companies' core technologies. 

The formulation combines Tristel's chlorine dioxide chemistry, which is sporicidal meaning that it has the highest level of disinfection efficacy, with ACTIZONE, a Solvay S.A. technology developed in collaboration with Byotrol and which enables a disinfectant to have long-lasting efficacy on a surface for an 8-hour period after first application. Tristel will incorporate the jointly developed formulation in several packaging formats under the family name "Tristel8". These products will be unique worldwide in combining sporicidal efficacy with residual disinfection efficacy.

Additional biocidal products

In addition, Byotrol will licence two biocidal formulations to Tristel for incorporation in its surface disinfectants range which is branded Cache. Cache represents a novel approach to today's very relevant issues of hospital hygiene and environmental concern. 

The Byotrol products and formulations give Tristel access to intermediate level disinfectants that are effective against bacteria, viruses and yeasts in accordance with the requirements of European Test Norms. The disinfectants will be for use in hospitals and will conform with the requirements of the European Biocidal Products Registration (BPR), and the United Kingdom equivalent that will come into force post Brexit. As this legislation is implemented throughout the United Kingdom and Europe during the coming years various active ingredients that are commonly incorporated in hospital grade disinfectants will be withdrawn from use. Tristel has previously incorporated some of these active ingredients in the intermediate level disinfectants that it presents to hospitals alongside its high-performance chlorine dioxide disinfectants. The Agreement will ensure that Tristel will continue to comply fully with the future regulatory environment that will govern the manufacture and sale of disinfectants for surface disinfection.

Commercial arrangements

Tristel will manufacture all the products deriving from the formulations, whilst Byotrol will supply the ACTIZONE material. Byotrol will receive payments from Tristel based upon volumes manufactured and product sales. Tristel will be responsible for branding and global sales and marketing through its thirteen subsidiaries and 35 international distributors. We expect sales of these new products to commence in the next financial year.

Commenting on the collaboration and current trading conditions, Paul Swinney, Chief Executive of Tristel, said: "Tristel and Byotrol are both specialist infection prevention companies, and in recent years we have forged a close working relationship. This collaboration holds great promise for both businesses. For Tristel it provides us a future-proofed intermediate grade disinfectant that we will incorporate into our hospital surface disinfectants product portfolio.

"The second key element of the arrangement is that we will combine a sporicidal high-performance disinfectant, which has an unrivalled kill time, with long-lasting disinfection activity that is proven to last for eight hours in accordance with PAS2424, a test developed with BSI and currently under detailed review by the EU for EN status. This combination of technologies creates a ground-breaking proposition. It is akin to clearing a crowd out of a stadium in 30 seconds and then keeping the doors closed to stop anyone re-entering. We must caution, however, that adoption of new infection prevention technology is often slow in healthcare, as both our companies know from first-hand experience.

"With respect to current trading conditions, we are experiencing very strong demand in all our markets due to the COVID-19 pandemic. As a UK manufacturer with very little exposure to convoluted international supply chains, and adequate productive capacity, we are well placed to meet the requirements of our customers in the UK and overseas."

For further information please contact: